晚期癌症队列中癌症相关血栓新型血浆蛋白质组生物标志物的开发
该研究在晚期癌症队列中采用Olink Explore HT血浆蛋白质组 panel 开展巢式病例对照研究,纳入57例癌症相关血栓(CAT)患者和113例匹配对照,构建随机生存森林模型预测早期血栓事件,30天时间依赖ROC达0.83,90天为0.73,180天降至0.67,重要蛋白富集于血小板活化、纤维蛋白凝块形成和补体级联调控等止血通路。
要点
- 血浆蛋白质组学模型对30天CAT预测区分度较好(时间依赖ROC 0.83),但随时间衰减。
- 重要蛋白富集于血小板活化、纤维蛋白凝块形成和补体级联调控等止血通路。
- 模型仅内部验证,需更大样本外部队列验证后方可用于风险预测。
核心结论
- 基于亲和的血浆蛋白质组学可作为识别癌症相关血栓生物标志物的新策略。
- 风险预测模型需在更大样本队列中进行外部验证。
研究设计与样本
- 巢式病例对照研究,使用Olink Explore HT panel检测血浆蛋白质组。
- 最终队列含57例CAT患者和113例匹配对照,来自5种选定癌症类型,样本采集于癌症诊断至化疗开始之间。
- 采用随机生存森林模型评估5416个归一化蛋白表达与8个临床变量和CAT的非线性关联。
主要发现
- 内部验证模型预测早期血栓事件较好,30天时间依赖ROC为0.83,90天为0.73,180天为0.67。
- 校准曲线随时间变化呈相似模式。
- 过度代表分析和基因集富集分析显示重要蛋白见于止血通路,包括血小板活化、纤维蛋白凝块形成和补体级联调控。
关键数值与推荐
- 时间依赖ROC:30天0.83,90天0.73,180天0.67。
临床怎么用
- 血浆蛋白质组学模型或有助于早期识别晚期癌症患者CAT高风险,但当前证据限于内部验证,尚不能直接用于临床风险分层。
局限性
- 需更大样本队列进行外部验证以确认风险预测模型的性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing risk models for cancer-associated thrombosis (CAT) show suboptimal performance in selective high-risk populations with cancer. Affinity-based plasma proteomics offers a novel approach for detecting CAT risk. OBJECTIVES: To identify plasma biomarkers for CAT using proximity extension assays in an advanced cancer cohort. METHODS: We performed a nested case-control study using the Olink Explore HT panel. The final cohort included 57 patients with CAT and 113 matched control patients from 5 selected cancer types who had samples collected between cancer diagnosis and chemotherapy initiation. Random survival forest model was used to assess nonlinear associations with CAT in 5416 normalized protein expressions and 8 clinical variables. Evaluation metrics averaged across bootstrapped out-of-bag test sets included time-dependent receiver operating characteristic curve, calibration plot, and cumulative incidence in high- vs low-risk predicted groups. We used SHapley Additive exPlanations values for feature interpretability. We performed overrepresentation analysis and gene set enrichment analysis to assess biological pathway plausibility. RESULTS: Our internally validated model predicted early thrombotic events well (time-dependent receiver operation characteristic value of 0.83 at 30 days and 0.73 at 90 days), but the discrimination waned with follow-up time (0.67 at 180 days). Calibration followed a similar pattern. In overrepresentation analysis and gene set enrichment analysis, important proteins were observed in hemostatic pathways, including platelet activation, fibrin clot formation, and complement cascade regulation. CONCLUSION: Affinity-based plasma proteomics can be used as a novel strategy to identify biomarkers of CAT. External validation with a larger sample size in a cohort setting is required for risk prediction models.
引用
- Preeti, Ranjan M, Pham D, et al. Development of novel plasma proteomic biomarkers for cancer-associated thrombosis in an advanced cancer cohort. J Thromb Haemost. 2026. PMID: 42107713. doi:10.1016/j.jtha.2026.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。